Open-Label Administration of Lisdexamfetamine Dimesylate Improves Executive Function Impairments and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adults

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Postgraduate medicine

• Publication date

  2010-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3810/pgm.2010.09.2196PMID 20861583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD

  2011cited by this paper
• NICE guideline: attention deficit hyperactivity disorder

  2010cited by this paper
• Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

  2010influential reference
• Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

  2009cited by this paper
• Executive Function Impairments in High IQ Adults With ADHD

  2009cited by this paper
• Effectiveness, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Optimization Study

  2009cited by this paper
• Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.

  2008cited by this paper
• Reliability, Validity, and Utility of Instruments for Self-Report and Informant Report Concerning Symptoms of ADHD in Adult Patients

  2008cited by this paper
• A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder

  2008cited by this paper
• Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study.

  2008cited by this paper
• [Effect of extended-release methylphenidate on the ecological executive function for attention deficit hyperactivity disorder].

  2007cited by this paper
• Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

  2007cited by this paper
• Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder

  2007cited by this paper
• Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

  2007cited by this paper
• A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.

  2007cited by this paper
• Methylphenidate Improves Aspects of Executive Function in African American Children With ADHD

  2006cited by this paper
• ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation

  2006cited by this paper
• Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder.

  2006influential reference
• Characterizing cognition in ADHD: beyond executive dysfunction.

  2006cited by this paper
• Mixed Amphetamine Salts Extended-Release in the Treatment of Adult ADHD: A Randomized, Controlled Trial

  2006cited by this paper
• A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder

  2006cited by this paper
• The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication.

  2006cited by this paper
• Does OROS*-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

  2006cited by this paper
• Remission versus response as the goal of therapy in ADHD: a new standard for the field?

  2006cited by this paper
• Executive functions in attention-deficit/hyperactivity disorder.

  2006cited by this paper
• Executive Functions and Attention Deficit Hyperactivity Disorder: Implications of two conflicting views

  2006cited by this paper
• Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review.

  2005cited by this paper
• Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes?

  2005cited by this paper
• Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD

  2005cited by this paper
• Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review.

  2004cited by this paper
• Introduction: Methodologies and models in the study of executive function

  2004cited by this paper
• Ecological validity of a simplified version of the multiple errands shopping test.

  2003cited by this paper
• DSM-IV: ADHD AND EXECUTIVE FUNCTION IMPAIRMENTS *

  2002cited by this paper
• ADHD Outside the Laboratory: Boys' Executive Function Performance on Tasks in Videogame Play and on a Visit to the Zoo

  2002cited by this paper
• Validation of the ADHD Rating Scale as a clirlician administered and scored instrument

  2001cited by this paper
• Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

  2001cited by this paper
• Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children

  1999cited by this paper
• Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD.

  1997influential reference
• Deficits in strategy application following frontal lobe damage in man.

  1991cited by this paper
• Child and Adolescent Psychiatry and Mental Health a 13-hour Laboratory School Study of Lisdexamfetamine Dimesylate in School-aged Children with Attention-deficit/hyperactivity Disorder

  year unknowncited by this paper

• Safety of Stimulants Across Patient Populations

  2025cites this paper
• Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.

  2024cites this paper
• Psychometric Properties of the Persian Version of Brown Attention Deficit Disorder Scale (BADDS)

  2022cites this paper
• Individualization of attention-deficit/hyperactivity disorder treatment: pharmacotherapy considerations by age and co-occurring conditions

  2020cites this paper
• The Effectiveness of Stimulant Medication at Improving Executive Functioning in Adults with ADHD

  2020cites this paper
• Improved Executive Function in Adults Diagnosed With Attention-Deficit/ Hyperactivity Disorder as Measured by the Brown Attention-Deficit Disorder Scale Following Treatment With SHP465 Mixed Amphetamine Salts Extended-Release: Post Hoc Analyses From 2 Randomized, Placebo-Controlled Studies

  2020influential citation
• A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects

  2019cites this paper
• Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge Eating Disorder (BED): a study protocol

  2019cites this paper
• A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK

  2017cites this paper
• Pharmacologic and Pharmacokinetic Aspects Lisdexamfetamine dimesylate is a water-soluble prodrug of the single isomer—d-amphetamine and l-lysine—that remains Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

  2017cites this paper
• A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI

  2016cites this paper
• World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction: prevalence, diagnosis, and treatment

  2015cites this paper
• New onset executive function difficulties at menopause: a possible role for lisdexamfetamine

  2015cites this paper
• Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.

  2014cites this paper
• Update on optimal use of lisdexamfetamine in the treatment of ADHD

  2013cites this paper
• Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.

  2013cites this paper
• Parent-Reported Executive Function Behaviors and Clinician Ratings of Attention-Deficit/Hyperactivity Disorder Symptoms in Children Treated with Lisdexamfetamine Dimesylate

  2013influential citation
• Stimulant Pharmacotherapy for Adults with ADHD

  2013cites this paper
• Attention-Deficit/Hyperactivity Disorder in a Chronic Care Paradigm

  2013cites this paper
• Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

  2013cites this paper
• Update on optimal use of lisdexamfetamine in the treatment of ADHD

  2013cites this paper
• Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the Effects of Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts on Cognition Throughout the Day in Adults with Attention-Deficit/Hyperactivity Disorder

  2013cites this paper
• Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review.

  2012cites this paper
• Diagnosis and management of adult attention-deficit/hyperactivity disorder.

  2012cites this paper
• Lisdexamfetamine Dimesylate

  2012cites this paper
• The use of lisdexamfetamine dimesylate for the treatment of ADHD

  2012cites this paper
• Diagnosis and Management of Attention-Deficit/Hyperactivity Disorder in Adults

  2012cites this paper
• Double-Blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in College Students With ADHD

  2012cites this paper
• Adult Attention-Deficit/Hyperactivity Disorder Treatment and Cardiovascular Implications

  2011cites this paper
• Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

  2011cites this paper
• Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults

  2011cites this paper
• Original article Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylatetreatmentinadults

  2011cites this paper